Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
GEREF (sermorelin acetate) is a synthetic growth hormone-releasing hormone (GHRH) analog administered by injection. It stimulates the anterior pituitary gland to release endogenous growth hormone, making it a diagnostic and therapeutic agent for growth hormone deficiency. The drug works by mimicking the body's natural GHRH signaling pathway.
With LOE approaching and no current patent data available, GEREF team is likely in defensive posture focused on retention rather than growth expansion.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
GEREF offers limited active career opportunities (zero linked jobs currently) as the product approaches loss of exclusivity. This role is best suited for professionals seeking stability in a niche endocrinology franchise or preparing for transition to generics management and post-LOE strategy.
Worked on GEREF at EMD Serono Research & Development Institute, Inc.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.